LTP·01learntopeptide
Healing & repairEvidence C2 cited

BPC-157 Arginate

aka BPC-157 stable salt · BPC arginine salt · oral BPC

BPC-157 Arginate is the arginine salt form of Body Protection Compound 157, a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. This formulation pairs the BPC-157 peptide with arginine as a counter-ion, which proponents claim provides improved stability and enhanced oral bioavailability compared to the standard acetate salt form. The underlying peptide consists of 15 amino acids and has demonstrated cytoprotective, anti-inflammatory, and tissue-healing properties across numerous preclinical studies. It promotes angiogenesis, modulates nitric oxide pathways, and upregulates growth factor expression. The arginate form is marketed as offering better gastric survival and systemic absorption when taken orally, though direct head-to-head comparative data remains limited.

Half-life
4 h
estimated
Tmax
1 h
Route
Subcutaneous injection

Sequence

One-letter15 residues

GEPPPGKPADDAGLV

Three-letter

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Read this before quoting the sequence
The peptide is identical to BPC-157. 'Arginate' denotes a salt form in which the peptide is paired with arginine as a counter-ion, marketed on the claim of improved solubility/stability. No peer-reviewed characterisation of the arginate salt itself (stoichiometry, formula, mass, CAS) was located in any primary, regulatory or database source in this pass; PubChem has no record for it.
Source ↗

Mechanism of action

BPC-157 Arginate shares the same fundamental mechanism as standard BPC-157. The pentadecapeptide interacts with the nitric oxide (NO) system, modulating both endothelial NOS and inducible NOS pathways. It promotes angiogenesis through upregulation of VEGF and its receptor VEGFR2, enhances collagen synthesis via COL1A1 gene expression, and modulates the FAK-paxillin signalling pathway involved in cell migration and wound healing. The arginine salt may provide additional NO substrate, potentially complementing the peptide NO-modulating effects.

What the evidence actually shows

Grade C

BPC-157 in general has extensive preclinical evidence from animal studies showing tissue-healing properties across multiple organ systems. However, human clinical trial data remains extremely limited for either form. Arginate-specific claims regarding improved bioavailability lack published comparative pharmacokinetic studies. Evidence relies on extrapolation from general BPC-157 preclinical data combined with theoretical advantages of the arginine salt formulation.

Regulatory status

Status
Not approved anywhere. The regulatory position is that of BPC-157: Sport Integrity Australia states BPC-157 is not approved by the TGA or any global regulatory authority for human use, and the FDA lists BPC-157 among bulk drug substances nominated for compounding but withdrawn from consideration.
Clinical stage
No trial of BPC-157 arginate is registered on ClinicalTrials.gov.
WADA
BPC-157 is prohibited at all times under WADA class S0 (Non-Approved Substances) per USADA and Sport Integrity Australia. No source retrieved names the arginate salt separately; salt form does not normally change prohibited-list status, but this is not asserted from a cited source.
Source ↗

Pharmacokinetics

Half-life
4 h
Tmax
1 h
Absorption
oral
Elimination
renal
Washout
3 days
Low-confidence pharmacokinetics
These figures are recorded as estimated rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Handling and storage

No compound-specific stability data exists
No published stability or storage data exists for the arginate salt specifically. The claim that arginate salt formation improves stability over the free peptide was not found in any peer-reviewed source. The general BPC-157 finding applies: the 2026 Pharmaceutics review states no formal stability, excipient compatibility or reconstitution studies have been done for BPC-157 in any salt form. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

References (2)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
molecularFormula, molecularWeight, casNumber, pubchemCid, storage.lyophilized, storage.reconstituted, storage.lightSensitive, reconstitution.solvent

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Healing & repair

BPC-157
A synthetic pentadecapeptide derived from a protein found in gastric juice. Studied for tissue repair, tendon/ligament healing, and gut protection in preclinical models.
GV1001
A 16-amino acid peptide derived from the active site of human telomerase reverse transcriptase (hTERT). Originally developed as a cancer immunotherapy vaccine, now investigated for anti-inflammatory and anti-aging properties.
KPV
A tripeptide derived from alpha-MSH, researched for anti-inflammatory effects in gut and intestinal tissue.